Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLalic, Samanta-
dc.contributor.authorJokanovic, Natali-
dc.contributor.authorIlomäki, Jenni-
dc.contributor.authorGisev, Natasa-
dc.contributor.authorLloyd, Belinda-
dc.contributor.authorLubman, Dan I-
dc.contributor.authorBell, J Simon-
dc.identifier.citationResearch in social & administrative pharmacy : RSAP 2019; 15(8): 925-935-
dc.description.abstractEvidence is accumulating globally on harms from extramedical prescription opioid analgesic (POA) use. The aim of this scoping review was to explore harms and documented risk factors associated with extramedical POA use in Australia. MEDLINE, EMBASE, PsycINFO and CINAHL were searched for original studies published between January 2000 and February 2018. Studies were eligible for inclusion if: 1) POA use was explicitly reported, 2) extramedical use was evident 3) harm was explicitly reported, 4) data were collected in/after 2000, 5) conducted in adults and 6) undertaken in Australia. We identified 560 articles and 16 met the inclusion criteria. Harms reported from extramedical POA use included: increased health service utilization (n = 5), non-fatal overdose (n = 6), fatal overdose (n = 5), injection-related injuries or diseases (n = 4), engagement in crime (n = 2), loss of employment (n = 1), and foreign body pulmonary embolization (n = 1). Multiple drug toxicity was reported as the cause of death in up to 83% of fatal overdose cases. Risk factors for harm included being male, aged 31-49 years, a history of chronic non-cancer pain, mental health disorders and/or substance abuse, and concomitant use of benzodiazepines, antidepressants or other centrally-acting substances. Extramedical use of POAs is associated with a range of harms, including fatal and non-fatal overdose. Polysubstance use with other centrally-acting substances was often implicated. No published studies used linked data sources to provide a comprehensive overview of the extent of POA use or harm in Australia. Future research should focus on undertaking longitudinal cohort studies with linked data sources.-
dc.subjectDrug overdose-
dc.subjectExtramedical use-
dc.subjectOpioid analgesics-
dc.titleHarms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review.-
dc.typeJournal Article-
dc.identifier.journaltitleResearch in social & administrative pharmacy : RSAP-
dc.identifier.affiliationSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australiaen
dc.identifier.affiliationCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia-
dc.identifier.affiliationTurning Point, Eastern Health, Melbourne, Australiaen
dc.identifier.affiliationEastern Health Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Box Hill, Australiaen
dc.identifier.affiliationPharmacy Department, Alfred Health, Melbourne, Australia-
dc.identifier.affiliationSchool of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia-
dc.identifier.affiliationNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia-
dc.identifier.affiliationPharmacy Department, Austin Health, Heidelberg, Victoria, Australia-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 6, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.